证券代码：603992 证券简称：松霖科技 公告编号：2025-085 转债代码：113651 转债简称：松霖转债 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 12 月 1 日 (二)股东会召开的地点：厦门市海沧区阳光西路 298 号 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 厦门松霖科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：关于终止实施 2023 年限制性股票激励计划暨回购注销相关限制性股 票的议案 | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 328,653,627 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 76.8715 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的 ...

北京植德（上海）律师事务所 关于厦门松霖科技股份有限公司 2025 年第三次临时股东会的 法律意见书 植德沪（会）字[2025]0052 号 二〇二五年十二月 上海市徐汇区虹桥路 183 号徐家汇中心三期 A 座办公楼 27 层（THREE itc） 邮编：200030 27 th Floor Tower A, THREE itc, No.183 Hongqiao Road, Xuhui District, Shanghai 200030 P.R.C 电话(Tel)：021-52533500 传真(Fax)：021-52533599 www.meritsandtree.com 北京植德（上海）律师事务所 关于厦门松霖科技股份有限公司 2025 年第三次临时股东会的 法律意见书 植德沪（会）字[2025]0052 号 致：厦门松霖科技股份有限公司（松霖科技/贵公司） 北京植德（上海）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2025 年第三次临时股东会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民 ...

Focus Review - The hard technology sector, particularly semiconductors and chips, remains mainstream with significant financing activities. For instance, Yanwei Semiconductor completed hundreds of millions in Series A financing, backed by notable investors like Yongxin Ark and Jinyuan Capital [4][15]. - In the health sector, medical devices are gaining attention, exemplified by Jingwei Vision's recent financing exceeding 100 million, supported by multiple investment funds [5][25]. - The internet sector is seeing advancements in AI, with Deep Principle securing over 100 million in Series A financing, led by Alibaba's fund and Ant Group [5][34]. Hard Technology - Yanwei Semiconductor completed hundreds of millions in Series A financing with investments from Yongxin Ark and Jinyuan Capital [4][15]. - Liding Microelectronics raised nearly 100 million in Series A financing, led by CMB International Capital [5][20]. - Hypershell, a consumer-grade exoskeleton company, announced a successful completion of 70 million USD in Pre-B and B rounds, achieving a post-financing valuation of nearly 400 million USD [7]. Health Sector - Jingwei Vision completed a new round of financing exceeding 100 million, with investments from various funds [5][25]. - Jiangsu Zhenyi Medical Technology announced the completion of several hundred million in Series C financing, backed by multiple investment institutions [5][30]. - Weike Biotechnology secured nearly 100 million in Series A financing, led by Shenzhen Capital Group [5][28]. Internet/Enterprise Services - Deep Principle, a pioneer in AI for Science, completed over 100 million in Series A financing, with participation from several major investors [5][34]. - Vision Future, a visual large model company, announced nearly 100 million in angel round financing, led by a listed company [5][35]. - Kulan Dream completed a million-level angel round financing, with investments from notable figures in the gaming industry [5][37].

Policy Developments - The National Health Commission will hold a press conference on November 27, 2025, to discuss the progress and effectiveness of grassroots medical and health services [1] Industry Initiatives - Beijing's Economic and Information Technology Bureau, along with six departments, has introduced measures to accelerate the promotion of artificial intelligence-assisted diagnostic technologies, including financial support of up to 50 million yuan for selected projects [2] Regulatory Approvals - Saikexide has obtained registration for three medical device products, enhancing its product range in the in vitro diagnostic field [3] - Xinhua Pharmaceutical has received a drug registration certificate for a compound local anesthetic cream, with an estimated sales revenue of 615 million yuan in 2024 [4] - Heng Rui Medicine has received approval for clinical trials of its innovative anti-tumor drug HRS-8364, with a cumulative R&D investment of approximately 21.65 million yuan [5] Capital Market Activities - Suzhou High-tech plans to sell a 47% stake in its medical device subsidiary for 604 million yuan [6] - Shanghai DeYin Technology has completed a Pre-A round financing of several million yuan, backed by listed company Songlin Technology [8] Industry News - Novartis China has responded to rumors of dissolving its county-level team, stating it will adjust its operational model while continuing to serve the county medical market [9] - Samsung Medical's subsidiary has been recommended as a candidate for a procurement project with a total expected amount of approximately 107 million yuan [10] Legal Matters - Foreign companies have filed a Section 337 investigation request against specific antibody-drug conjugates, alleging infringement of trade secrets, involving companies from the US, Netherlands, and China [11] Shareholder Actions - Bid Pharma's shareholder plans to reduce their stake by up to 0.16% between December 17, 2025, and March 16, 2026, due to funding needs [12]

厦门松霖科技股份有限公司 2025 年第三次临时股东会 会议资料 证券代码：603992 二〇二五年十二月 1 | | | 厦门松霖科技股份有限公司 2025 年第三次临时股东会通知 一、召开会议的基本情况 （一）股东会类型和届次 2025 年第三次临时股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的 方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 1 日 14 点 30 分 厦门松霖科技股份有限公司 2025 年第三次临时股东会 召开地点：厦门市海沧区阳光西路 298 号 （五）网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自 2025 年 12 月 1 日 至 2025 年 12 月 1 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会 召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平 台的投票时间为股东会召开当日的 9:15-15:00。 （六）融资融券、转融通、约定购回 ...

| 证券代码：603992 | 证券简称：松霖科技 | 公告编号：2025-084 | | --- | --- | --- | | 转债代码：113651 | 转债简称：松霖转债 | | 厦门松霖科技股份有限公司 关于 2023 年限制性股票激励计划首次授予部分第一个解 除限售期解除限售暨上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股 数为2,778,000股。 本次股票上市流通总数为2,778,000股。 本次股票上市流通日期为2025 年 11 月 24 日。 2025年11月13日，厦门松霖科技股份有限公司（以下简称"公 司"或"松霖科技"）召开第三届董事会第二十七次会议，审议通过 了《关于2023年限制性股票激励计划首次授予部分第一个解除限售 期解除限售条件成就的议案》，现就相关事项说明如下： 一、2023 年限制性股票激励计划批准及实施情况 （一）2023 年限制性股票激励计划已履行的相关程序 1、2023 年 11 月 30 ...

Core Viewpoint - Songlin Technology announced that shareholder Ms. Zhou Lihua plans to reduce her holdings by up to 200,000 shares, representing 0.05% of the company's total share capital [1] Summary by Relevant Sections - **Shareholder Information** - Ms. Zhou Lihua directly holds 2,970,188 shares, accounting for 0.69% of the company's total share capital [1] - The shares were acquired before the company's initial public offering and became tradable after the lifting of restrictions on August 25, 2022 [1] - **Reduction Plan** - Ms. Zhou Lihua intends to reduce her holdings through centralized bidding [1] - The maximum number of shares to be sold is 200,000 [1]

Core Viewpoint - The company has decided to terminate the 2023 restricted stock incentive plan due to changes in the international economic and trade environment, as well as the need for strategic upgrades, which do not align with the current development needs of the company [1] Group 1 - The company will not proceed with the second and third phases of the restricted stock incentive plan, nor the reserved grants [1] - All restricted stocks granted under this incentive plan that have not yet been released from restrictions will be repurchased and canceled [1] - Related documents, including the implementation assessment management measures for the 2023 restricted stock incentive plan, will also be terminated [1]

Core Viewpoint - Songlin Technology (603992.SH) has decided to terminate its 2023 restricted stock incentive plan due to changes in the international economic and trade macro environment, as well as the company's strategic iteration and upgrade, which do not align with the current development needs of the company [1] Group 1 - The company believes that the current restricted stock incentive plan cannot meet the expected incentive goals and effects that align core employee work objectives with the company's development needs [1] - The decision includes the termination of the second and third phases of the incentive plan and the repurchase and cancellation of all restricted stocks that have been granted but not yet released from restrictions [1] - Related documents, including the "Implementation Assessment Management Measures for the 2023 Restricted Stock Incentive Plan of Xiamen Songlin Technology Co., Ltd.", will also be terminated [1]

Core Viewpoint - Songlin Technology (603992.SH) announced that shareholder Zhou Lihua plans to reduce holdings through centralized bidding, with a total reduction not exceeding 200,000 shares, accounting for 0.05% of the company's total share capital [1] Summary by Relevant Sections - Shareholder Action - Zhou Lihua intends to reduce holdings by up to 200,000 shares [1] - This reduction represents 0.05% of the total share capital of Songlin Technology [1]